Trial Profile
Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone; Hyaluronidase; Lenalidomide
- Indications Multiple myeloma; Plasmacytoma
- Focus Registrational; Therapeutic Use
- Acronyms POLLUX
- Sponsors Janssen Research & Development; Janssen-Cilag
- 15 Jun 2023 Results comparing the effectiveness of talquetamab in MonumenTAL-1 (NCT03399799/NCT04636552), vs physicians choice (PC) therapy CASTOR , POLLUX , EQUULEUS , APOLLO, presented at the 28th Congress of the European Haematology Association
- 01 May 2023 Comparative results of Efficacy of Teclistamab from NCT04557098 Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials , published in the Clinical Lymphoma, Myeloma & Leukemia
- 04 Jan 2023 Results of final analysis reporting updated efficacy and safety data for overall survival published in the Journal of Clinical Oncology